March 5, 2021
The anti-allergy treatment Alesion (epinastine) was the best-selling product in the Japan pharma market in February, dethroning MSD’s PD-1 inhibitor Keytruda (pembrolizumab), according to a monthly snapshot report released by Encise. Alesion racked up 9.7 billion yen in the month...read more